Pharma Advisory
Problem
Molecular strategy decisions are made early in a programme and are expensive to revisit once trials are running.
How collaboration works
Independent scientific review of biomarker rationale, patient-selection strategy and the molecular assumptions underlying a development plan.
Typical engagement
Advisory sessions, written scientific review, or standing advisory involvement across a programme.
Potential deliverables
- Written scientific assessment
- Biomarker strategy review
- Documented risk and assumption register